Optimization of chronic lymphocytic leukemia treatment using game theory
- 8 December 2021
- journal article
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
Abstract
The current strategy of chronic lymphocytic leukemia (CLL) treatment is based on genetic risk factors such as del(17p), TP53 mutations and/or unmutated variant of IGHV genes. Guidelines recommend the usage of targeted drugs, e.g. ibrutinib, in the first line for patients with unfavorable risk factors due to dismal results of other treatment options. Unfortunately, in real-life treatment decisions are often made without full knowledge of genetic risk factors in the treated patient. Our aim was to find the optimal therapeutic strategy for such patients, that is, those providing the best 5-year progression-free survival (PFS). Using a relatively simple game theory-based approach we here show, that currently, the used strategy is more advantageous (success rate 71%) compared to administration of immunochemotherapy to all patients (success rate with fludarabine + cyclophosphamide + rituximab — 45%, bendamustine + rituximab — 32%). However, the optimal strategy for CLL treatment in the conditions of unknown genetic risks is the administration of ibrutinib to all patients (success rate 73%). Our simple method can be used for optimization of treatment strategy of any oncologic disease and can be integrated into relevant clinical decision support systems.Keywords
This publication has 9 references indexed in Scilit:
- Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatmentAmerican Journal of Hematology, 2019
- Optimizing Cancer Treatment Using Game TheoryJAMA Oncology, 2019
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLThe New England Journal of Medicine, 2018
- IGHV mutational status testing in chronic lymphocytic leukemiaAmerican Journal of Hematology, 2017
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trialThe Lancet Oncology, 2016
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trialBlood, 2016
- Games of life and death: antibiotic resistance and production through the lens of evolutionary game theoryCurrent Opinion in Microbiology, 2014
- Risk categories and refractory CLL in the era of chemoimmunotherapyBlood, 2012
- An Approach for Leukemia Classification Based on Cooperative Game TheoryAnalytical Cellular Pathology, 2011